bullish
Strategic Review of Essa Pharma: Potential 27% Upside Amidst Halted Trials and Strong Shareholder Alignment
131 Views07 Nov 2024 16:15
Essa Pharma (EPIX) halted pipeline development, launched a strategic review, with NAV/liquidation value estimated at $2.18/share.
What is covered in the Full Insight:
- Strategic Review Overview
- Shareholder and Management Alignment
- Financial Assessment
- Concerns and Risk Factors
- Leadership Background
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Special Situation Investments
Event-Driven Investment Opportunities
Price Chart(Sign Up to Access)
- Loading...
x